Home/Products/VILDACROSS 50 TAB
VILDACROSS 50 TAB
— Product

VILDACROSS 50 TAB

VILDAGLIPTIN 50MG

VILDACROSS 50 TAB is a tablet of vildagliptin 50 mg, a DPP-4 inhibitor. It is used in type 2 diabetes mellitus to improve glycaemic control, working by enhancing the body's own incretin hormones to increase insulin release and reduce glucagon after meals.

Enquire about this product → Back to catalog
01

Benefits

  • Enhances endogenous incretin activity, increasing insulin release only when blood glucose is raised.
  • Because the action is glucose-dependent, it carries a very low risk of hypoglycaemia when used alone.
  • Weight-neutral, unlike sulphonylureas, pioglitazone and insulin.
  • Well tolerated, with a side-effect profile close to placebo in most patients.
  • A useful option in the elderly and where hypoglycaemia would be particularly hazardous.
02

Side effects

Not everyone gets these. Most are mild and settle as the course finishes.

Common
  • Headache
  • Dizziness
  • Nausea
  • Nasopharyngitis or upper respiratory symptoms
Less common
  • Constipation or diarrhoea
  • Peripheral oedema
  • Raised liver enzymes on testing
  • Joint pain
Stop and get medical help if any of these occur
  • Severe persistent abdominal pain radiating to the back, with vomiting — this may be acute pancreatitis
  • Yellowing of the skin or eyes, dark urine, or persistent nausea and loss of appetite
  • Severe or disabling joint pain
  • Blistering skin lesions, which may indicate bullous pemphigoid
  • Swelling of the face, lips or tongue, or difficulty breathing
03

Precautions

  • Check liver function before starting and at intervals during the first year. Vildagliptin has been associated with hepatic dysfunction, and this monitoring is specifically recommended for this agent.
  • Stop immediately and investigate if jaundice or other signs of liver injury appear.
  • DPP-4 inhibitors have been associated with acute pancreatitis. Stop at once if severe persistent abdominal pain occurs, and avoid in a history of pancreatitis.
  • Contraindicated in type 1 diabetes, in diabetic ketoacidosis, and in significant hepatic impairment.
  • Dose reduction is required in moderate to severe renal impairment.
  • Hypoglycaemia risk rises when combined with a sulphonylurea or insulin — those doses often need reducing.
  • Bullous pemphigoid has been reported with DPP-4 inhibitors; stop and refer if blistering skin lesions develop.
  • Contraindicated in pregnancy and breastfeeding.